A Drug for the Treatment and Prevention of Pneumonia with COVID-19 was Registered in Russia
OREANDA-NEWS. On May 25, the Russian Ministry of Health registered the inhaled drug Leitragin for the treatment and prevention of pneumonia, which complicates the course of coronavirus infection. This was reported on Wednesday on the website of the Federal Medical and Biological Agency (FMBA), which developed the drug.
"The new drug is intended for the treatment and prevention of pneumonia, which complicates the course of coronavirus infection," according to the website of the developer - the Federal Biomedical Agency.
It is noted that the industrial production of this drug is now starting.
In August last year, FMBA received three patents at once as part of the development of Leytragin: on the treatment of COVID-19, on the prevention of pneumonia and severe complications, on the use in combination with another medicine.
The creators claimed to have identified new properties of the hexapeptide. As a result, it is the first and only delta-opioid receptor agonist in the world to be used in practical medicine.
Leitragin is the first drug aimed at preventing and combating the cytokine storm that aggravates the course of COVID-19. Clinical studies among 320 patients with a moderate course of COVID-19 showed that those who received the drug did not have a single death, as well as cases of transition of the disease to a more severe form. The recovery time for patients taking Leutragin was reduced to eight days compared to 14 days for those receiving standard therapy.